日本神经科医生对晚期帕金森病设备辅助治疗偏好的数据集

数据集获取（Figshare）

• 源站标题：Neurologists’ preferences for device-aided therapy for advanced Parkinson’s disease in Japan
• DOI：10.6084/m9.figshare.21310580.v1
• 发布日期：2022-10-11
• 文件数：3 个
• 文件总体积：121.51 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/Neurologists_preferences_for_device-aided_therapy_for_advanced_Parkinson_s_disease_in_Japan/21310580

命令行下载

curl -L -o "icmo_a_2129800_sm7287.docx" "https://ndownloader.figshare.com/files/37812110"
curl -L -o "icmo_a_2129800_sm7286.docx" "https://ndownloader.figshare.com/files/37812113"
curl -L -o "icmo_a_2129800_sm7285.docx" "https://ndownloader.figshare.com/files/37812116"

文件清单

• icmo_a_2129800_sm7287.docx（37.29 KB）
• icmo_a_2129800_sm7286.docx（54.28 KB）
• icmo_a_2129800_sm7285.docx（29.95 KB）

文件总体积 121.51 KB（源站 API 实测）。

数据说明

This study measures the relative preference for attributes of device-aided therapies (DATs) for advanced Parkinson’s Disease (PD) from the perspective of Japanese neurologists.
Attributes and levels were elicited based on literature and interviews with certified neurologists experienced with DATs. An online survey including a discrete choice experiment (DCE) was developed, pilot tested, and distributed through an online panel to neurologists treating advanced PD patients. Participants were asked to choose treatments among several choice sets of two hypothetical DATs described only by the attributes, or no DAT (continuing oral treatment). A conditional logit model using the Bayesian framework was developed to estimate the marginal utilities of attributes’ levels, and the relative utility of treatments available to Japanese advanced PD patients or being developed in Japan was assessed.
The DCE survey completed by 308 neurologists showed that the attributes with the greatest influence on DAT selection were surgery requirement (relative importance of 28%), average increase in the duration of daily “on” time without dyskinesia which affects daily activities (15%), average change in cognitive function related to treatment introduction (15%), device management frequency (14%), average number of pills of oral PD medication after treatment introduction (13%), average influence of treatment on symptoms of depression (12%), and type of device (large/small) (3%). All attributes significantly influenced respondents’ choices, except for external device type. Experience with DATs did not influence the directions of preferences. Out of treatment profiles representing DATs, continuous subcutaneous infusion of levodopa-carbidopa had a higher preference score than levodopa-carbidopa intestinal gel infusion and deep brain stimulation.
Our findings suggest that Japanese neurologists would prefer a DAT without surgery requirement. Other factors related to efficacy, safety, and administration mode have a significant, but a smaller influence on prescription choices.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.21310580.v1（source: https://tandf.figshare.com/articles/dataset/Neurologists_preferences_for_device-aided_therapy_for_advanced_Parkinson_s_disease_in_Japan/21310580）。